Skip to main content
Premium Trial:

Request an Annual Quote

UgenTec, LGC Biosearch Technologies to Launch Coronavirus Detection Workflow

NEW YORK — Belgian molecular diagnostics software developer UgenTec has partnered with LGC Biosearch Technologies to launch an artificial intelligence-based workflow for the detection of the 2019-nCoV coronavirus, the companies said on Wednesday.

Specific terms of the alliance were not disclosed.

According to the companies, the research-use-only workflow is based on UgenTec's flagship FastFinder PCR diagnostics software platform and Biosearch's reagents. The workflow is compatible with common PCR devices and can transfer de-identified and anonymized test results to disease control organizations.

"In times like these, labs have to respond to crises fast and handle increasing volumes of samples with existing personnel," UgenTec CEO Steven Verhoeven said in a statement. "With our software, labs are able to standardize the interpretation of results and simplify the communication with government disease centers."

Biosearch, a subsidiary of London-based LGC, recently began expediting availability of its Black Hole and Blackberry Quenchers and other dyes and components for use in 2019-nCoV diagnostic kits.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.